Ischemic Ooptic Neuropathy
Conditions
Interventions
the group of hydrobromide anisodine:Intravenous infusion, 2mg / day
the group of xuesetong injection (lyophilized):Intravenous infusion, 400mg / day
Sponsors
Sichuan Provincial People‘s Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patients who are primary ocular ischemic lesions. 2. The patients whose duration don't exceed 3 months; 3. The patients whose age are 18-65, including men and women; 4. The patients who could understand and voluntarily sign ICF.
Exclusion criteria
Exclusion criteria: 1. The patients who have other severe eye disease which would influence visual functionsuch as glaucoma, corneal inflammation and opacity, uveitis, clear lens opacity, diabetic proliferative retinopathy, temporal arteritic anterior ischemic neuropathy, macular hole, retinal detachment, retinitis pigmentosa; 2. The patients who have brain hemorrhage and optic canal fracture; 3. The patients who have no light perception over a week; 4. The patients who have severe heart disease, severe arrhythmia, heart failure; 5. The patients who have severe hypertension or severe lipid metabolic disorders; 6. The patients whose Liver and kidney function are severely abnormal (ALT> 1.5 ULN, Cr> 1.5 ULN); 7. The patients who are taking drugs with plaque formation by transcranial Doppler; 8. The patients who are allergies, and allergic to two or more drugs or food, or allergy to the drug ingredient; 9. The patients who already pregnant, would plan to pregnancy or breast-feeding women; 10. The patients who had participate in other clinical trials over the past three months; 11.The patients is not suitable to participate in this study who the researchers determine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The total effective rate of disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| Vision Rating;Perspective ratings;Visual evoked potentials; | — |
Contacts
Public ContactWu Zhengzheng
Outcome results
None listed